BioSight
Companies
Nuvalent, Inc. logo

NUVL

NASDAQCAMBRIDGE, MA
Nuvalent, Inc.

Nuvalent is a clinical-stage biopharmaceutical company developing small-molecule targeted therapies, with lead programs including zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330 in preclinical and clinical testing. The company is focused on discovering and developing product candidates through a risk-mitigated strategy, with plans to pursue regulatory filings with the FDA and foreign regulatory authorities. Nuvalent is working to scale manufacturing capabilities to support potential future commercialization of its product candidates.

$100.28+30.66%1Y
NUVL · daily close · illustrative · 0 catalysts marked
$62$76$89$103$117Apr '25Aug '25Dec '25Apr '26
1Y high$111.991Y low$66.72range$45.27(68%)past catalysts

Pipeline2

neladalkib
UnknownIndication pending review
zidesamtinib
UnknownIndication pending review

Catalyst Calendar2

Past (2)
Q3
'25
NDAzidesamtinib
“The Company plans to initiate a rolling NDA submission in July 2025 with completion targeted for the third quarter of 2025”
8-K ↗
H2
'25
Enroll.neladalkib
“the Company expects to begin enrollment early in the second half of 2025”
8-K ↗

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar